Hybridoma Technology: Monoclonal Antibody Production Explained

Added:

Recombinant Antibody Technologies and Phage Display

While hybridoma technology is the historical standard for monoclonal antibody (mAb) production, it faces significant criticism and competition from modern recombinant technologies, such as phage display and single B-cell cloning. Critics of hybridomas highlight several limitations: the heavy reliance on animal immunization (raising ethical concerns), the time-consuming fusion and selection process, and the risk of genetic instability in hybridoma cell lines. Furthermore, hybridomas initially yield rodent antibodies, which require complex 'humanization' to avoid triggering immunogenic responses in human patients. In contrast, recombinant methods like phage display bypass animal immunization entirely. By using vast synthetic or donor-derived genetic libraries, researchers can rapidly screen and select fully human antibodies in vitro. This alternative perspective argues that recombinant platforms are faster, more ethically sustainable, and better suited for generating highly specific therapeutic antibodies against toxic or weakly immunogenic targets that traditional hybridoma systems cannot effectively process.

Basic structure and function of antibodies (immunoglobulins) and how they bind to specific antigens.
The biology of B-lymphocytes (B-cells), including how they are activated and differentiate into antibody-secreting plasma cells.
The distinction between monoclonal and polyclonal antibodies, and why monoclonal specificity is highly desirable.
Fundamental cell culture concepts, particularly the characteristics of myeloma cells (cancerous, immortalized immune cells).
The de novo and salvage pathways of nucleotide synthesis, which form the biochemical basis of HAT selection.
Therapeutic applications of monoclonal antibodies (mAbs) in medicine, such as immunotherapy for cancer and autoimmune diseases.
Diagnostic applications of monoclonal antibodies in clinical and research settings, including ELISA, immunohistochemistry, and pregnancy tests.
The limitations of murine (mouse) hybridomas and the development of chimeric, humanized, and fully human antibodies to prevent human anti-mouse antibody (HAMA) responses.
Alternative, modern methods of antibody generation, such as phage display technology and recombinant antibody production.
Bioprocess engineering concepts for scaling up monoclonal antibody production in bioreactors for industrial and pharmaceutical use.
214.2K views3.5Klikes10:09@FrankLecturesOriginal Release: 2017-10-12

Hybridoma technology, developed by Georges J.F. Kohler and César Milstein in 1975 and awarded the Nobel Prize in 1984, is a method for producing monoclonal antibodies by fusing antigen-specific B lymphocytes with immortal myeloma cells (lacking HGPRT and immunoglobulin genes), followed by selection in HAT medium to isolate hybrid cells that can produce identical antibodies targeting a single epitope on an antigen.